Hikma Pharmaceuticals (HIK) Stock Rating Reaffirmed by Peel Hunt
Hikma Pharmaceuticals (LON:HIK)‘s stock had its “hold” rating reaffirmed by investment analysts at Peel Hunt in a research report issued on Thursday. They currently have a GBX 1,390 ($19.52) price target on the stock. Peel Hunt’s target price would indicate a potential upside of 43.74% from the stock’s previous close.
A number of other research analysts have also weighed in on HIK. Jefferies Group reaffirmed an “underperform” rating and issued a GBX 895 ($12.57) price target on shares of Hikma Pharmaceuticals in a research note on Wednesday, January 17th. decreased their price target on shares of Hikma Pharmaceuticals from GBX 1,060 ($14.89) to GBX 865 ($12.15) and set a “reduce” rating on the stock in a research note on Friday, November 10th. JPMorgan Chase & Co. decreased their price target on shares of Hikma Pharmaceuticals from GBX 1,250 ($17.55) to GBX 1,000 ($14.04) and set a “neutral” rating on the stock in a research note on Friday, November 10th. Stifel Nicolaus decreased their price target on shares of Hikma Pharmaceuticals from GBX 1,320 ($18.54) to GBX 1,000 ($14.04) and set a “hold” rating on the stock in a research note on Thursday, November 9th. Finally, Numis Securities raised shares of Hikma Pharmaceuticals to a “buy” rating and set a GBX 1,300 ($18.26) price target on the stock in a research note on Thursday, November 9th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the stock. Hikma Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of GBX 1,171 ($16.44).
Hikma Pharmaceuticals (HIK) opened at GBX 967 ($13.58) on Thursday. The firm has a market cap of $2,320.00 and a PE ratio of 1,973.47. Hikma Pharmaceuticals has a 12 month low of GBX 906.50 ($12.73) and a 12 month high of GBX 2,346 ($32.94).
COPYRIGHT VIOLATION NOTICE: “Hikma Pharmaceuticals (HIK) Stock Rating Reaffirmed by Peel Hunt” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2018/02/01/hikma-pharmaceuticals-hik-stock-rating-reaffirmed-by-peel-hunt.html.
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.